“The present problem has uncovered some structural weaknesses in the EU’s medicines supply chain and a substantial dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides said. She encouraged that supply chain concerns be addressed within an EU pharmaceutical system envisioned being released by the end in the 12 mont